UPDATE -- Tempus Announces $200 Million in Series F Financing
May 30, 2019 09:02 ET
|
Tempus
CHICAGO, May 30, 2019 (GLOBE NEWSWIRE) -- Tempus, a leading technology company advancing precision medicine through the collection and analysis of molecular and clinical data, announced today an...
Tempus Announces $200 Million in Series F Financing
May 30, 2019 06:00 ET
|
Tempus
CHICAGO, May 30, 2019 (GLOBE NEWSWIRE) -- Tempus, a leading technology company advancing precision medicine through the collection and analysis of molecular and clinical data, announced today an...
ASCO and Tempus Announce Collaboration to Help Research Sites Identify Potential Participants for the Targeted Agent and Profiling Utilization (TAPUR™) Study
January 10, 2019 11:00 ET
|
Tempus
ALEXANDRIA, Va. and CHICAGO, Jan. 10, 2019 (GLOBE NEWSWIRE) -- The American Society of Clinical Oncology, Inc. (ASCO) and Tempus announced today an agreement to support research sites participating...
Tempus Launches New Mobile App to Make Clinical and Genomic Data More Accessible to Physicians at the Point of Care
September 19, 2018 10:00 ET
|
Tempus
CHICAGO, Sept. 19, 2018 (GLOBE NEWSWIRE) -- Tempus, a leading technology company advancing precision medicine through the collection and analysis of molecular and clinical data, today announced the...
Tempus Announces $110 Million in Series E Financing
August 29, 2018 10:00 ET
|
Tempus
CHICAGO, Aug. 29, 2018 (GLOBE NEWSWIRE) -- Tempus, a leading technology company advancing precision medicine through the collection and analysis of molecular and clinical data, announced today it...
Tempus to Participate in the NCI-MATCH Clinical Trial
August 02, 2018 10:30 ET
|
Tempus
Having met rigorous qualifications, Tempus joins a select group of commercial and academic laboratories designated to cast a wider net for patients to enter the trial CHICAGO, Aug. 02, 2018 (GLOBE...
Tempus Announces New Initiative to Support Physicians Efforts to Deliver Personalized Medicine
May 08, 2018 13:27 ET
|
Tempus
CHICAGO, May 08, 2018 (GLOBE NEWSWIRE) -- Tempus today announced a new initiative that will allow physicians to sequence a second patient sample without additional charge, removing a barrier that...
Tempus Launches Tempus xE, Whole Exome Sequencing to Empower Data-Driven Cancer Care and Research
February 22, 2018 10:30 ET
|
Tempus
CHICAGO, Feb. 22, 2018 (GLOBE NEWSWIRE) -- Tempus, a technology company focused on helping doctors personalize cancer care by collecting and analyzing large volumes of molecular and clinical data,...
Tempus and NYU School of Medicine Announce New Initiative to Help Improve Outcomes for Pancreatic Cancer Patients
January 25, 2018 10:30 ET
|
Tempus
CHICAGO, Jan. 25, 2018 (GLOBE NEWSWIRE) -- Tempus, a technology company focused on helping doctors personalize cancer care by collecting and analyzing large volumes of molecular and clinical data,...
Tempus and Vanderbilt-Ingram Cancer Center Announce Data Initiative to Improve Outcomes for Cancer Patients
January 04, 2018 11:00 ET
|
Tempus
CHICAGO, Jan. 04, 2018 (GLOBE NEWSWIRE) -- Tempus, a technology company focused on helping doctors personalize cancer care by collecting and analyzing large volumes of molecular and clinical data,...